Therapeutic Impacts of Tocotrienols and Boerhaavia diffusa on Cholesterol Dynamics, Lipid Hydroperoxidation and Antioxidant status on Hyperlipidemic Rats: Induced by Oxidized Cholesterol by Fouzia Ishaq3, Samir Chettri2, and Deepti Malhotra4, Amir Khan1,*, Abhay Singh Chandel2,
Recent Research in Science and Technology 2011, 3(11): 13-21 
ISSN: 2076-5061 
www.scholarjournals.org 
 
 
www.recent-science.com 
13 
 
RRST-Biochemistry 
Therapeutic Impacts of Tocotrienols and Boerhaavia diffusa on 
Cholesterol Dynamics, Lipid Hydroperoxidation and Antioxidant 
status on Hyperlipidemic Rats: Induced by Oxidized Cholesterol 
Amir Khan1,*, Abhay Singh Chandel2, Fouzia Ishaq3, Samir Chettri2, and Deepti Malhotra4 
1Department of Biomedical Science, Dolphin P.G. Institute of Biomedical and Natural Sciences, Dehradun, UK, India 
2Department of Biotechnology, HNB Garhwal University, Srinagar, UK, India 
3Department of Zoology and Environment Science, Gurukul Kangri University, Haridwar UK, India 
4Department of Biotechnology, Shri Guru Ram Rai (P.G.) College, Dehradun, UK, India 
Article Info 
 
Abstract 
Article History 
 
Cholesterol, the prominent member of steroid family, present in tissues and in plasma either 
as free cholesterol or as a storage form combined with a long chain fatty acid as cholesteryl 
ester. High blood cholesterol results in Atherosclerosis, which is characterized by presence 
of atheromas. In this we investigated the efficacy of antioxidant and hypolipidemic agents 
Tocotrienols and Boerhaavia diffusa by analyzing all the parameters in plasma lipoprotein 
lipids, TL, TC, TG, VLDL-C, LDL-C, non-HDL-C, MDA and in-vitro oxidizability of LDL, as 
investigated in oxidized cholesterol feeded rats treated with and without Tocotrienols and 
Boerhaavia diffusa. All the plasma lipids parameters, TL, TC, TG, VLDL-C, LDL-C, non-HDL-
C and MDA levels were significantly increased in hyperlipidemic control rats. After 4 weeks 
administration of Tocotrienols and Boerhaavia diffusa significantly reduced the overall 
oxidative burden and effectively ameliorated the above altered parameters. 
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Introduction 
Coronary heart disease (CHD) is the main cause of death 
in Western countries and Asia. Among CHDs, ischemic heart 
disease (IHD) leads to the highest mortality rate. The number 
of heart patients suffering from IHD worldwide is gradually 
increasing [1]. Several epidemiological studies have 
demonstrated the relationship between plasma cholesterol 
levels and the development of IHD. Cholesterol, the most 
prominent member of steroid family, is an important 
component of eukaryotic membranes [2]. Cholesterol is 
present in tissues and in plasma either as free cholesterol or 
as a storage form, combined with a long-chain fatty acid as 
cholesteryl ester. In plasma, both forms are transported in 
lipoproteins. It is synthesized in many tissues from acetyl-CoA 
and is the precursor of all other steroids in the body such as 
corticosteroids, sex hormones, bile acids, and vitamin D. Lipids 
are transported through plasma compartment in lipoproteins, 
which are complex water soluble molecules consisting of a 
core of cholesteryl esters and TG covered by a surface 
monolayer of phospholipids, free cholesterol and 
apolipoproteins. In the last two decades, there have been 
major advances in our understanding of the role of plasma 
lipoproteins, apolipoproteins, lipolytic enzymes, and lipoprotein 
receptors in cholesterol and lipoprotein metabolism. This new 
information has provided major insights into the role of 
cholesterol and lipoproteins in the pathogenesis of premature 
atherosclerosis. There are six major classes of human plasma 
lipoproteins, these include chylomicrons, very low density 
lipoproteins (VLDL), intermediate density lipoprotein (IDL), low 
density lipoprotein (LDL), high density lipoprotein (HDL) and 
lipoprotein (a) [Lp(a)] [3]. Nuclear magnetic resonance 
subdivides the lipoproteins in plasma into the following 
subclasses: (1) for VLDL, V6-V1 with V6 the largest and V1 the 
smallest; (2) IDL; (3) for LDL, L3-L1 with L1 being the smallest 
and dense [4]. HDL can be further separated by hydrated 
density into HDL2a, HDL2b, HDL3a, HDL3b and HDL3c, [5]. 
These lipoproteins are distinguished on the basis of their lipid 
content, ultracentrifugation size, electrophoretic mobility and 
surface proteins. Fifteen major human plasma apolipoproteins 
have been identified and their gene and protein structures 
determined [6]. Atherosclerosis is a progressive disease and 
results due to the deposition of intracellular lipids in the smooth 
muscle cells of the inner arterial wall. These lesions narrow 
and eventually block the arteries due to the formation of 
fibrous, calcified plaques. The rough arterial wall promotes the 
formation of blood clots, which may also block the artery. Due 
to the blocking of arteries, blood flow stops and causes the 
death of the deprived tissues. The stoppage of blood flow is 
known as an infraction. The cholesterol lowering effect of 
tocotrienols was attributed mainly to their down regulation of 
HMG-CoA reductase-the rate-limiting enzyme of the 
cholesterol biosynthetic pathway. Boerhaavia diffusa is a 
medicinal plant widely used in the Ayurvedic medicine [7]. The 
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plant was named in honour of Hermann Boerhaave, a famous 
Dutch physician of the 18th century [8]. Boerhaavia diffusa 
(Spreading Hogweed in English) belonging to the family of the 
Nyctaginaceae, is mainly diffused perennial herbaceous 
creeping weed of India (known also under its traditional name 
as punarnava). The first pharmacological studies have 
demonstrated that the root of punarnava exhibits a wide range 
of properties: anti-inflammatory [9], diuretic, laxative [8], anti-
urethritis febrifuge, antileprotic, anti-ashmatic, antiscabby and 
antistress activites. An aqueous extract of thinner roots of B. 
diffusa at a dose of 2 mg/kg exhibited the remarkable 
protection of various enzymes such as serum glutanic-
ocaloacetic transaminase, serum glutanic-pyruvic 
transaminase, and bilirubin in serum against hepatic injury in 
rats [10]. As discussed above, hypercholestolamia is a major 
risk factor for the development of artherosclerosis and is 
associated with coronary and peripheral vascular disease. In 
this study we investigated the efficacy of antioxidant agent 
tocotrienols and Boerhavvia diffusa by analyzing all the 
parameters in plasma, TC, VLDL-C, LDL-C, HDL-C, TBAR, 
MDA, Hepatic TG, TC and antioxidant enzymes (CAT, SOD, 
GPx and GRED) as well as in vitro oxidizability of LDL. 
Material and Methods 
Chemicals: 1-Chloro 2, 4-Dinitrobenzene was purchased from 
Central drug house, Pvt. Ltd. (India). All other chemicals used 
for this study were of analytical grade and obtained from 
HIMEDIA (India), Sisco (India), Ashirwad (India), Sigma-Aldrich 
(USA), Miles (USA), Acros (USA) and Tocotrienols drug as 
well as RBD palm olein were supplied as a gift from 
CAROTECH BHD, Chemor, Malaysia. 
Estimation: Plasma triglyceride [11], Plasma Cholesterol, LDL 
and HDL [12], Plasma VLDL-C [13], Fractionation of Plasma 
lipoprotein such as LDL [14], HDL and its fractions-HDL2, HDL3 
[15], Plasma FRAP [16], ex vivo and in vitro Cu++-mediated 
LDL oxidation [17, 18] were measured by following known 
procedures. 
Plant Material:-The samples of the roots of Boerhaavia diffusa 
(Nyctaginaceae), collected in Aligarh (UP) were kindly provided 
by Prof. Siddiqui (Taxonomist), Department of Botany, Aligarh 
Muslim University, Aligarh, India and the voucher specimen 
(AMUBT8977) has been preserved in our research laboratory 
(Dept. of Biochemistry, J.N. Medical College, AMU, Aligarh) for 
future reference in research. 
Preparation of Plant Extract: 250 gm of powder dried roots of 
Boerhaavia diffusa were taken in the round bottom flask of 
Soxhlet apparatus then 1 litre of ethanol was added. Refluxing 
was carried out for 48 hours. Further solvent was evaporated 
and its extract was calculated per gm of dried material. 
Pourslin chip are add in the refluxing process to avoid 
bumping. 
Experimental Design: The experimental study was approved 
by the Dolphin Institute of Biomedical and Natural Science, 
Dehradun, Uttarakhand, where the study was conducted. The 
rats were given pelleted rat chow. Maintenance and treatment 
of all the animals was done in accordance with the principles of 
Institutional Animal Ethics Committee constituted as per the 
directions of the Committee for the Purpose of Control and 
Supervision of Experiments on Animals (CPCSEA), India. 
Healthy male albino rats, weighing about 150-180 g were 
purchased from Indian Veterinary Research Institute (IVRI), 
Bareilly (India), were maintained to animal house 
environmental condition prior to the experiment. For the 
present study, animals were divided into following 4 groups: 
Normal Control (NC); six rats were given 1.0 ml 
saline/rat/day through gastric intubation for 4 weeks, 
Hyperlipidemic control rats (HC); six rats in this group were 
administered 1.0 mg oxidized cholesterol/rat/day through 
gastric intubation for 4 weeks, Hyperlipidemic Tocotrienols 
Treated Rats (H-T3T); six rats in this group were given 6.0 mg 
Tocotrienols/rat/day through gastric intubation for 4 weeks and 
Hyperlipidemic Boerhaavia diffusa Treated Rats (H-BT);  six 
rats in this group were given 1.0 Boerhaavia diffusa mg/rat/day 
through gastric intubation for 4 weeks 
Collection of Blood and Plasma: For the estimation of 
different parameters, overnight fasted rats in each group were 
anaesthetized and blood drawn from cardiac puncture, and 
were collected in heparinised tube. Plasma was separated 
from blood by centrifugation at 2500 rpm for 30 min.  
Statistical evaluation: This was done by employing two-tailed 
Student t-test as described by Bennet and Franklin [19]. P 
value less than 0.02 were considered significant. 
Results 
Impacts of Tocotrienols and Boerhaavia diffusa on 
average body weight in each group of rats: As seen in 
Table 1, depicts that the average body weight (g) of 
hyperlipidemic control rats (H-C), Tocotrienols  treated (H-T3T) 
and Boerhaavia diffusa treated (H-BT) rats was 180, 179 and 
182  (g), respectively, whereas for normal control (H-C) rats 
the average body weight was 150 g, whereas, the average 
body weight of H-C, H-T3T and H-BT rats showed a significant 
gain of 39%, 29% and 23% respectively after 4 weeks of 
treatment. These results demonstrate that in hyperlipidemic 
Tocotrienols treated rats the gain in body weight after 4 weeks 
was significantly higher than rats in H-C group.
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Table 1: Impacts of Tocotrienols and B. diffusa on average body weight in each group of rats after 4 weeks of treatment. *Values are mean ± SD 
from 6 rats in each group, N-C, normal control; H-C, hyperlipidemic control; H-T3T, fed 6 mg Tocotrienol/rat/day and H-BT, given 1mg B.D/rat/day for 
4 weeks. Significantly different from N-C at ap<0.001. Significantly different from H-C at ap<0.001. 
Average body weight/rat (g) 
Group Before treatment After Treatment 
N-C 150.23±1.23* 210.11±3.12 (+39.85%)a 
H-C 
 
180.22±6.21* 
 
212.63±1.42 
(+17.98%)a 
H-T3T 
 
179.11±3.22* 
 
232.33±6.11 
(+29.71%)a 
H-BT 
 
182.13±4.11* 
 
224.11±3.61 
(+23.04%)a 
 
Impacts of Tocotrienols and B. diffusa on Plasma Lipids, 
Plasma Lipoprotein Lipids, and Lipid Peroxidation Status 
in Plasma in Hyperlipidemic Rats Treated for 4 Weeks: 
Effect on plasma lipids: As seen in Fig. 1, all the plasma 
lipids parameters were significantly increased in 
hyperlipidemic control (H-C) rats, when compared to N-C 
values. Total lipids (TL), triglycerides (TG), free fatty acids 
(FFA) and total cholesterol (TC) significantly increased from 
340, 53, 132 and 86 mg/dl in N-C to 523, 112,149 and 151 
mg/dl, respectively, in H-C group. After 4 weeks of 
Tocotrienols treatment, levels of TL, TG, FFA and TC were 
significantly decreased by 10%, 41%, 10% and 28%, 
respectively, when compared to corresponding H-C values. 
Whereas, in Boerhaavia diffusa treated rats, TL, TG, FFA and 
TC levels were significantly reduced by 8%, 42%, 12% and 
34% respectively, in comparison to corresponding values in 
H-C group. These results demonstrate that 4-week treatment 
of hyperlipidemic rats with 6 mg Tocotrienols and 1 mg 
Boerhaavia diffusa mediated a similar and significant 
reduction in above lipid parameters.
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Impacts of Tocotrienols and Boerhaavia diffusa on Plasma Total Lipid, Triglycerides, Free Fatty Acid and Total Cholesterol in Oxidized 
Cholesterol Feeded Rats after 4 weeks of treatment, *Values are mean (mg/dl) ± SD from pooled plasma of 6 rats in each group, N-C, normal 
control; H-C, hyperlipidemic control; H-T3T, fed 6 mg Tocotrienol/rat/day and H-BT, given 1mg B.D/rat/day for 4 weeks, Significantly different from N-
C at ap < 0.001, Significantly different from H-C at ap<0.001 and bp<0.05. 
 
Effects on plasma lipoprotein lipids on the ratios of LDL-
C/HDL-C and HDL-C/TC: As seen in Fig.2, plasma VLDL-C, 
LDL-C and non-HDL-C levels were significantly increased from 
13, 54 and 63 mg/dl in N-C to 21 mg/dl (88%), 115 mg/dl (113%) 
and 133 mg/dl (113%) respectively, in H-C. After 4 weeks of 
Tocotrienols and Boerhaavia diffusa treatment, both VLDL-C, 
LDL-C and non-HDL-C levels showed a significant reduction 
41%, 44% and 43%, respectively, in H-T3T, whereas, in H-BT, 
VLDL-C, LDL-C and non-HDL-C  were significantly reduced of 
41%, 48% and 46%, respectively, in comparison to 
corresponding values in H-C rats. HDL-C, HDL2-C and HDL3-C 
levels were decreased from 21, 7 and 14 mg/dl in N-C to 18 
mg/dl (14%), 5 mg/dl (30%) and 13 mg/dl (10%), respectively, in 
H-C values. After 4 weeks of Tocotrienols treatment (H-T3T) 
HDL-C, HDL2-C and HDL3-C levels showed a significant 
increase of 72%, 160% and 42%, respectively, when compared 
to corresponding values in H-C, whereas, in H-BT, HDL-C, 
HDL2-C and HDL3-C levels were increased by 55%, 120% and 
37%, respectively. These results demonstrate that both 
Tocotrienols and Boerhaavia diffusa are equally effective in 
reducing VLDL-C and LDL-C levels. On the other hand, in 
comparison to H-C values, treatment of hyperlipidemic rats with 
Tocotrienols mediated a significantly higher increase in HDL-C, 
HDL2-C and HDL3-C concentration than the increase seen in 
Lovastatin treated rats. On the other hand, as shown in Table 2, 
LDL-C/HDL-C and HDL-C/TC ratios were calculated from the 
data presented in Fig. 1 and 2. LDL-C/HDL-C ratio was 
significantly increased from 3.83 in N-C to 8.19 (113%) in H-C 
group, when compared to ratio in N-C. After 4 weeks of 
treatment, the increase in LDL-C/HDL-C ratio was significantly 
prevented and decreased to 3.50 and 3.55 in H-T3T and H-BT, 
respectively and HDL-C/TC ratio was significantly decreased 
from 0.343 in N-C to 0.212 (38%) in H-C group. Tocotrienols and 
Boerhaavia diffusa treatment to these rats significantly prevented 
the increase in HDL-C/TC ratios and fully restored them near to 
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the N-C. In addition, the ratios related to HDL-C in Tocotrienols 
and Boerhaavia diffusa treated rats were positively modulated 
and restored similar to normal control value, indicating 
normalization of cholesterol levels associated with the above 
lipoproteins.
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Impacts of Tocotrienols and Boerhaavia diffusa on Plasma VLDL-C, LDL-C, HDL-C, HDL2-C and HDL3-C sub-fractions and Non-HDL-C in 
Cholesterol feeded rats after 4 weeks of treatment, Values are mean (mg/dl) ± SD from pooled plasma of 6 rats in each group, N-C, normal control; 
H-C, hyperlipidemic control; H-T3T, fed 6 mg Tocotrienol/rat/day and H-BT, given 1mg B.D/rat/day for 4 weeks, Significantly different from N-C at 
ap<0.001 and bp<0.02, Significantly different from H-C at ap<0.001. 
 
Table 2: Effects of Tocotrienols and Boerhaavia diffusa on the Ratio of LDL-C/HDL-C and HDL-C/TC in Cholesterol feeded rats after 4 weeks of 
treatment, †For the calculation of ratios, data is taken from Fig. 1 and 2. *Values are mean ± SD from pooled plasma of 6 rats in each group, N-C, 
normal control; H-C, hyperlipidemic control; H-T3T, fed 6 mg Tocotrienol/rat/day and H-BT, given 1mg Boerhaavia diffusa/rat/day for 4 weeks. 
Significantly different from N-C at ap<0.001 and bp<0.01. Significantly different from H-C at ap<0.001, bp<0.05 
Ratio† Group 
N-C H-C H-T3T H-BT 
LDL-C/HDL-C 3.83±0.014* 8.19±0.061* 
(+113.83 %)a 
3.50±0.816* 
(-56.26 %)a 
3.55±0.019* 
(-56.65 %)a 
HDL-C/TC 0.343±0.060 
 
0.212±0.003 
(-38.19 %)b 
0.386±0.061 
(+82.07 %)b 
0.356±0.088 
(+67.92 %)b 
 
Lipid Lowering Effect on liver triglycerides and total 
cholesterol: As seen in Table 3, hepatic levels of triglyceride 
(TG) and total cholesterol (TC) were significantly increased in 
hyperlipidemic rats (H-C) by 29 % and 124 % respectively, 
when compared to corresponding values in H-C. Feeding of 
Tocotrienols  and Boerhaavia diffusa to hyperlipidemic rats for 
4 weeks was associated with a significant decline in liver TG 
and TC levels by 24 % and 40 % respectively, in H-T3T, 
whereas, in H-BT group, TG, TC and FFA levels were 
reduced by 7 % and 42 % respectively, when compared to 
corresponding values in S-C group. These results 
demonstrate that similar to plasma TG and TC levels in liver 
was significantly increased in hyperlipidemic rats. In addition, 
feeding of Tocotrienols and Boerhaavia diffusa to 
hyperlipidemic rats resulted in a significant decline of TG and 
TC to a level similar to corresponding values in H-C. The 
combined results demonstrate that levels of TG, TC in plasma 
and liver lipids were significantly increased in hyperlipidemic 
rats. Treatment of these stressed rats with 6 mg Tocotrienols 
/rat/day or 1 mg Boerhaavia diffusa/rat/day mediated a 
significantly decline in the above lipid parameters, similar to 
corresponding values in H-C rats.
  
Table 3: Effects of Tocotrienols and Boerhaavia diffusa on Liver Triglycerides (TG) and Total cholesterol (TC) contents in cholesterol feeded rats 
after 4 weeks of treatment. *Values are mean ± SD from homogenate of pooled liver 6 rats in each group, N-C, normal control; H-C, Hyperlipidemic 
control; H-T3T, fed 6 mg Tocotrienols/rat/day and H-BT, given 1mg Boerhaavia diffusa/rat/day for 4 weeks. Significantly different from N-C at 
ap<0.001, Significantly different from H-C at ap<0.001. 
Group Liver Homogenate 
Triglycerides 
(mg /100mg protein) 
Total cholesterol 
(mg /100mg protein) 
N-C 0.634±0.003* 2.19±0.042 
H-C 0.821±0.081* 
(+29.34%)a 
4.92±0.031 
(+124.65%)a 
H-T3T 0.630±0.151* 
(-23.26%)a 
2.98±0.139 
(-39.43%)a 
H-BT 0.768±0.139* 
(-6.45%)a 
2.83±0.190 
(-42.47%)a 
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Impacts on plasma total antioxidants and lipid peroxidation 
products: As seen in Fig. 3, depicts the antioxidant impacts of 
Tocotrienols and Boerhaavia diffusa on plasma concentrations 
of total antioxidants, conjugated diene (CD), lipid hydroperoxide 
(LHPO) and malondialdehyde (MDA) in hyperlipidemic (H-C) 
rats. In H-C rats, plasma total antioxidants level was reduced 
from a control value of 43 to 30 (30%) μmole/dl. Treatment of 
H-C rats with Tocotrienols and Boerhaavia diffusa for 4 weeks 
resulted in a significant increase of total antioxidants levels by 
31 % and 20 %, when compared to H-C value. The oxidative 
stress induced in H-C rats significantly enhanced plasma lipid 
peroxidation products, such as conjugated diene, lipid 
hydroperoxide and MDA. Formation of conjugated diene, lipid 
hydroperoxide and MDA in plasma was increased from 8.32, 
1.52 and 2.83 in N-C to 13.38 (60 %), 1.95 (59 %) and 3.23 
(107 %) μmole/dl, respectively, in H-C. After Tocotrienols  
treatment, in H-T3T,  a significant decrease of 14 %, 17 % and 
32 % was seen in the formation of conjugated diene, lipid 
hydroperoxide and MDA, respectively, when compared to 
corresponding values in H-C rats. Similarly in H-BT, conjugated 
diene, lipid hydroperoxide and MDA in plasma were also 
significantly decreased by 8 %, 13 % and 29 %, respectively, 
when compared to corresponding values in H-C rats. These 
results demonstrate that in H-C rats, due to increase in 
oxidative stress, total antioxidants level was decreased, 
whereas, concentration of plasma conjugated diene, lipid 
hydroperoxide and MDA were significantly increased. 
Tocotrienols or Boerhaavia diffusa treatment significantly 
restored the total antioxidants level and blocked the increase in 
plasma conjugated diene, lipid hydroperoxide and MDA to a 
level close to corresponding normal values.
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Antioxidant impacts of tocotrienols and Boerhaavia diffusa on plasma Total antioxidants, Conjugated diene, Lipid hydroperoxide and 
Malondialdehyde contents in cholesterol feeded rats after 4 weeks of treatment. *Values are mean (µmole/dl) ± SD from pooled plasma of 6 rats in 
each group, N-C, normal control; H-C, hyperlipidemic control; H-T3T, fed 6 mg Tocotrienol/rat/day and H-BT, given 1mg B.D/rat/day for 4 weeks. 
Significantly different from N-C at ap<0.001. Significantly different from H-C at ap<0.001 and bp<0.05. 
 
Impacts on the regulation of hepatic Catalase and 
Superoxide dismutase, Glutathione peroxidase and 
Glutathione reductase activities: As seen in Table 4, 
Catalase activity in liver was significantly decreased from a 
value of 3.22 unit in N-C to 2.12 (35 %) in H-C, respectively. 
Administration of Tocotrienols to hyperlipidemic rats (H-T3T) 
resulted in a significant increase in liver catalase activities by 
3.10 (46 %) unit, respectively. In Boerhaavia diffusa treated 
(H-BT) group, liver catalase activity was significantly 
increased by 43 %. However, in comparison to corresponding 
tissue values of normal control rats (N-C), the decline in 
hepatic SOD activity of hyperlipidemic rats was 17 %. 
Treatment of Tocotrienols and Boerhaavia diffusa 
hyperlipidemic rats resulted in a significant increase in 
hepatic SOD activity by 30 % and 27 %, respectively from 
normal value. In hyperlipidemic rats, Gpx activity in liver was 
significantly increased from a value of 52 unit in N-C to 65 (23 
%), respectively, in H-C rats. As evident, after 4 weeks of 
treatment with Tocotrienols, Gpx activity in liver was 
significantly decreased by 25 %. In H-BT rats, the Gpx activity 
in liver was decreased by 24 % respectively, when compared 
to corresponding tissue values in H-C group. On the other 
hand, in hyperlipidemic rats, the enzymatic activities of 
hepatic Gred were decreased significantly by 23 % when 
compared to corresponding values of H-C rats. Feeding of 
Tocotrienols and Boerhaavia diffusa to hyperlipidemic rats 
significantly blocked the decrease in hepatic Gred activities 
and increased them to a similar value of 15 % respectively. 
Administration of Tocotrienols and Boerhaavia diffusa to 
hyperlipidemic rats significantly prevented the decrease in 
Gred activity and increased to a level, which is similar to 
normal value. In summary, hepatic catalase, SOD, Gpx and 
Gred enzymes, which constitute a mutually supportive team 
of defense against ROS, are significantly decreased in 
hyperlipidemic rats. However, feeding of Tocotrienols and 
Boerhaavia diffusa substantially quenches these free radicals 
(ROS), thus positively normalizing the above enzyme levels.
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Table 4: Impacts of Tocotrienols and Boerhaavia diffusa on liver catalase, superoxide dismutase, glutathione peroxidase and glutathione reductase 
activities in cholesterol feeded rats after 4 weeks of treatment. †One unit (U/mg protein) of enzyme activity is defined as the µmoles of H2O2 
decomposed/min/mg protein. ‡One unit (U/mg protein) of enzyme activity is defined as the amount of enzyme required to inhibit O.D. at 560 nm of 
chromogen production by 50 % in one minute. +One unit (U/ mg protein) of enzyme activity is defined as nmole oxidized glutathione formed/min/mg 
homogenate protein. ‡One unit (U/ mg protein) of enzyme activity is defined as nmole NADPH oxidized/min/mg PMS protein. *Values are mean ± SD 
from homogenate or PMS fraction of pooled liver of 6 rats in each group, N-C, normal control; H-C, Hyperlipidemic control; H-T3T, fed 6 mg 
Tocotrienol/rat/day and H-BT, given 1mg B.D/rat/day for 4 weeks. Significantly different from N-C at ap<0.001. Significantly different from H-C at 
ap<0.001 
Group 
 
Catalase† 
 
 
Superoxide dismutase†† 
 
Glutathione            
peroxidase+ 
Glutathione          
reductase‡ 
 
N-C 3.22±0.132* 0.611±0.004 52.32±0.101* 10.68±0.215 
H-C 
 
2.12±0.631* 
(-34.16 %)a 
0.505±0.210 
(-17.34 %)a 
65.13±1.15* 
(+24.48%)a 
8.32±0.219 
(-22.09%)a 
H-T3T 
 
3.10±0.261* 
(+46.22 %)a 
0.658±0.134 
(+27.32 %)a 
49.33±1.89* 
(-24.25%)a 
9.49±0.161 
(+14.06.76%)a 
H-BT 
 
3.02±0.448* 
(+42.45 %)a 
0.643±0.521 
(+27.32 %)a 
50.13±1.24* 
(-23.03%)a 
9.62±0.639 
(+15.62%)a 
 
Antioxidant effects on basal levels of conjugated diene 
formation and lag phase in LDL: As depicted in Table 5, the 
ex vivo base line diene conjugation (BDC) levels of LDL in 
hyperlipidemic rats was increased by 48 % respectively, in 
comparison to the corresponding N-C values. Feeding of 
Tocotrienols to hyperlipidemic rats partially blocked the in vivo 
oxidation of LDL and reduced their BDC levels by 19 % 
respectively. Similarly, after Boerhaavia diffusa treatment (H-
BT), BDC levels in was reduced by 19 % respectively, in 
comparison to the corresponding H-C values.  As expected, 
the lag phase time of LDL oxidation was reduced from 88 min 
in N-C to 56 min in H-C. Treatment of hyperlipidemic rats with 
Tocotrienols Boerhaavia diffusa restored the lag phase time of 
LDL oxidation to 79 min and 68 min, respectively.
 
Table 5: Ex- vivo and Copper-mediated in vitro oxidation of LDL in cholesterol feeded rats after 4 weeks of Tocotrienols and Boerhaavia diffusa 
treatment. *The conjugated diene (CD) values are expressed as nmole malondialdehyde equivalents/mg protein. Basal conjugated diene represent 
the status of oxidized LDL in vivo. **The lag phase is defined as the interval between the intercept of the tangent of the slope of the curve with the 
time expressed in minutes. +Values are obtained from LDL, isolated from pooled plasma of 6 rats in each group, N-C, normal control; H-C, 
Hyperlipidemic control; H-T3T, fed 6 mg Tocotrienol/rat/day and H-BT, given 1mg B.D/rat/day for 4 weeks. †Percent increase with respect to basal 
value in N-C, ††Percent decrease with respect to basal value in H-C, ¶Percent decrease with respect to lag phase value in N-C, §Percent increase 
with respect to lag phase value in H-C. 
 
Group 
LDL OXIDATION 
Basal value of CD* Lag phase** 
N-C 170.22+ 88 
H-C 
 
251.82+ 
(+47.93%) † 
56 
(- 36.36%) ¶ 
H-T3T 
 
202.61+ 
(-19.54%) †† 
79 
(+41.07%) § 
H-BT 
 
205.27+ 
(-18.48%) †† 
68 
(+21.42%) § 
 
Discussion 
Results from the present study, indicates that 
hypercholestrolemic rats experience an exaggerated oxidative 
stress when compared with hypocholesterolemic rats. The 
oxidized cholesterol induced extensive proatherogenic 
changes, that occurred in rats, were reflected on a variety of 
parameters, such as, plasma and lipoprotein lipids including 
cholesterol and apoB content of LDL and its subfractions, 
plasma lipid peroxidation products including  ex vivo and in 
vitro oxidizability of LDL, plasma total antioxidants and HDL-
associated activities, MDA release and antioxidant enzymes in 
erythrocytes. Supplementation of rats with dietary Tocotrienols 
(Tocomin) and Boerhaavia diffusa (B.D) for 4 weeks 
significantly reduced the overall oxidative burden and 
effectively ameliorated the above altered parameters, thus, 
indicating a strong hypolipidemic/antiatherogenic and 
antioxidant effect of Tocomin and Boerhaavia diffusa. Four-
week Tocomin and Boerhaavia diffusa treatment of these 
hypercholestrolemic rats caused a significant reduction in 
plasma LDL oxidation, which were reversed to 45% and 50% 
of respective control values of hypochlolesterolemic rats. 
These results indicate a strong protective effect of dietary 
tocotrienols and Boerhaavia diffusa, which may help lower the 
risk of myocardial infarction in hypercholestrolemic rats. Our 
results indicate a modest and significant increase in plasma 
total lipid, TG, TC and free fatty acids (FFA) in 
hypercholestrolemic rats. The increase in plasma TG levels is 
apparently due to an increase in VLDL which can be the result 
of either increased VLDL production or decreased VLDL 
clearance. It is possible that massive free radical load in 
hypercholestrolemic rats may stimulate VLDL production by 
increasing adipose tissue lipolysis, increasing hepatic de novo 
fatty acid synthesis, and decreasing hepatic fatty acid 
oxidation, all of which provide fatty acid substrate for 
esterification into TG and assembly into VLDL particles in the 
liver as well as increase in plasma FFA. Tocomin and 
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Boerhaavia diffusa effectively blocked the increase in the 
above lipid parameters and reversed them to a level similar to 
their respective control values of hypocholesterolemic rats. 
Therefore, tocotrienols may exert their cholesterol lowering 
effect in hyperlipidemic rats in a similar manner as previously 
reported for hyperlipidemic animals [20, 21] and humans [22, 
23]. Mechanism wise, as previously shown in HepG2 cells, as 
well as in normolipidemic and hyperlipidemic rats, tocotrienols 
reduce cholesterol synthesis by suppressing HMG-CoA 
reductase activity, which in turn is reduced by a decline in its 
protein mass [20, 24]. The decline in protein mass may be 
achieved by inhibition of HMG-CoA reductase synthesis and/or 
enhanced degradation. Consistent with in vivo results in rats 
[20], γ-tocotrienol has been shown to mediate the suppression 
of enzymatic activity and protein mass of HMG-CoA reductase 
in HepG2 cells through decreased synthesis (57 % of control) 
and enhanced degradation (2.4-fold versus control) of the 
enzyme [24]. In addition, γ-tocotrienol was shown to upregulate 
LDL receptor in mammalian cells and may be implicated in part 
for the reduction of apoB-lipoprotein in vivo [24]. Thus, 
tocotrienols reduce cholesterol formation in mammalian cells 
by suppressing HMG-CoA reductase activity through two 
actions: decreasing the efficiency of translation of HMG-CoA 
reductase mRNA and increasing the controlled degradation of 
HMG-CoA reductase protein, post-transcriptionally [24].  In 
addition, another report indicates that γ-tocotrienol influences 
apoB secretion by both cotranslational and posttranslational 
processes involving a decreased rate of apoB translocation 
and accelerated degradation of apoB in HepG2 cells. This 
activity correlated with a decrease in free and esterified 
cholesterol [25]. Taken together, the information indicates an 
association between the suppression of hepatic cholesterol 
synthesis and apoB secretion, and the observed lowering of 
apoB and LDL-C levels in animal and human models [26]. 
Oxidative modification of lipoproteins is believed to play a 
central role in the pathogenesis of atherosclerosis [27]. 
Because plasma contains several antioxidants [28] and 
lipoproteins with oxidative damage have been isolated from 
atherosclerotic lesions [27], lipoprotein oxidation generally is 
considered to occur in the vessel wall. Although lipid oxidation 
in the vessel wall is thought to occur as a result of a local 
deficiency of endogenous antioxidants or an excess of free 
metal ions, only limited data support these hypotheses. 
Research has shown that human atherosclerotic plaques 
contain massive amounts of lipid peroxidation products, 
despite the presence of large quantities of α-tocopherol 
(vitamin E) and ascorbate [29]. Therefore, it is unclear whether 
oxidized lipoproteins originate in the arterial wall or are 
produced in the circulation and then enter the intimal space. 
Our data show that due to sustained high cholesterol diet in 
hypercholestrolemic rats, oxidation of lipid/lipoprotein particles 
is considerably enhanced. Conjugated diene (which measure 
the initial phase of lipid peroxidation), lipid hydroperoxide 
(intermediate product of lipid peroxidation) and MDA (which 
measure the degradation phase of lipid peroxidation) in plasma 
are significantly increased in hypercholestrolemic rats. The 
increase in plasma lipid peroxidation products is associated 
with a significant decline in plasma total antioxidants. The 
former suggests increased production of oxidants while later 
indicates diminished antioxidant defense. Both the changes 
indicate an existence of profound oxidative stress. Our results 
indicate a significant decrease in plasma lipid peroxidation 
products with a concomitant and significant increase in plasma 
total antioxidants in Tocomin and Boerhaavia diffusa treated 
hypercholestrolemic rats. In this context, our data provide 
suggestive evidence for the increased CVD risk observed in 
hypercholestrolemic rats. In addition, daily intake of 
tocotrienols as a dietary supplement will be useful in the 
prevention and treatment of hypercholesterolemia induced 
dyslipidemia and atherosclerosis. The levels of reactive oxygen 
species (ROS) are controlled by antioxidant enzymes, 
superoxide dismutase (SOD), catalase (CAT), glutathione 
peroxidase (Gpx), glutathione reductase (Gred). An impaired 
radical scavenger function has been linked to decreased 
activity of enzymatic of free radicals. These enzymes are 
important in defending the body against free radicals as well as 
toxic substances by converting them to a form that can be 
readily excreted. Therefore, any changes in these enzymes 
could be potentially detrimental to the host by altering these 
defense mechanisms. Normal cellular metabolism involves the 
production of ROS, low levels of ROS are vital for proper cell 
functioning, while excessive in vivo generation of these 
products can adversely affect cell functioning. 
Malondialdehyde (MDA) is one of the final products of lipid 
peroxidation in human cells, and an increase in ROS causes 
over production of MDA, which is considered a surrogate 
marker of oxidative stress. Increased MDA production in 
erythrocytes is known to cause a decrease in the membrane 
fluidity of the membrane lipid bilayer and increased osmotic 
stability of cells. The major intracellular antioxidant enzyme, 
SOD, specifically converts superoxide radicals to hydrogen 
peroxide, CAT as well as Gpx detoxifies hydrogen peroxide to 
water [30]. Glutathione peroxidase protects against free radical 
injury by reducing the peroxide concentration via a glutathione 
dependent reduction process, thereby reducing the amount of 
peroxides available to produce cellular damage. Reduced 
glutathione is a major intracellular non-protein sulfhydryl 
compound. It has many biological functions, including 
maintenance of membrane protein and lipoprotein SH groups 
in the reduced form, the oxidation of which can otherwise 
cause altered cellular structure and function. Glutathione cycle 
operates in the erythrocytes for the disposal of H2O2 generated 
in the cell supplementing the function of CAT. Glutathione and 
H2O2 are twin substrates for Gpx. Glutathione is formed from 
its oxidized form, GSSG by the enzyme Gred, which requires 
NADPH as a cofactor [31] therefore, as the balance between 
ROS production and antioxidant defenses is lost, the resultant 
oxidative stress through a series of events deregulates the 
cellular functions leading to various pathological conditions. An 
antioxidant compound might contribute partial or total 
alleviation of such damage. Treatment of hypercholestrolemic 
rats with dietary tocotrienols and Boerhaavia diffusa for 4 
weeks significantly improved the integrity of erythrocytes 
membrane as shown by improved protection against lipid 
peroxidation as well as reversal of SOD, CAT, Gpx and Gred 
activities to near normal levels. Similar to our results, a 
reversal in the erythrocytes SOD and GPx activities has 
previously been reported in healthy cholesterolemic rats 
supplemented with 200 mg of TRF for 4 weeks.  It is interesting 
to mention that in general, the results obtained from the 
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oxidized cholesterol feeded hypercholestrolemic rats treated 
with dietary tocotrienols and Boerhaavia diffusa exhibited great 
similarities with the results in supplementation for 4 weeks. In 
addition, in this rat model, the hypochlolesterolemic and 
antioxidative properties of Boerhaavia diffusa are also 
comparable to Tocomin, used in animal model. First, we have 
summarized the similarities between the common parameters 
investigated in both the agents. These reports clearly indicate 
that daily intake of routine dietary antioxidant vitamins or their 
heavy dose supplements by hypercholestrolemic rats will not 
sufficiently alleviate the enormous in vivo oxidative 
stress/damage induced by oxidized cholesterol. However, 
since, dietary tocotrienols and Boerhaavia diffusa, because of 
their potent hypochlolesterolemic/anti-atherogenic and 
antioxidant actions, were able to substantially 
ameliorate/normalize all the altered parameters including 
atheroprotective function of HDL described in the thesis, we 
initially recommend daily supplementation of 
hypercholestrolemic patients with dietary tocotrienols 
(Tocomin). In conclusion, based on Tocomin and Boerhaavia 
diffusa mediated multiple therapeutic benefits, described in the 
present study, daily intake of tocotrienols as a dietary 
supplement and Boerhaavia diffusa, as herbal supplementation 
may be useful in the prevention and treatment of high 
cholesterol mediated atherosclerosis. In addition, daily use of 
dietary tocotrienols will be efficacious, cost effective, and good 
source of vitamin E.  
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